Drug Trial Radar · NCT05945537
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Sep 8, 2023
Primary completion
May 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Inipharm Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A, B, D and F and in participants with a history of MASH or presumed MASH in Part C and in participants with MASH in E.
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis
Interventions
INI-822 (A)Drug
Different dose levels of INI-822
Placebo (B)Other
Matching placebo to INI-822
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs).Time frame: Part A: Up to 5 Weeks
- Incidence of adverse events (AEs).Time frame: Part A fasted fed crossover cohort: Up to 8 weeks
- Incidence of adverse events (AEs).Time frame: Part B: Up to 7 weeks
- Incidence of adverse events (AEs).Time frame: Part C: Up to 9 weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part A: Up to 5 Weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part A fasted fed crossover cohort: Up to 8 weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part B: Up to 7 weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part C: Up to 9 weeks
- Incidence of adverse events (AEs)Time frame: Part E: Up to 12 weeks
- Incidence of adverse events (AEs)Time frame: Part F: Up to 2 weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part E: Up to 12Weeks
- Number of participants with clinical laboratory abnormalitiesTime frame: Part F: Up to 2Weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Campbelltown Hospital, Level 10, building A, Campbelltown Hospital, Therry Road,
Campbelltown, New South Wales (nsw), Australia · Recruiting
Genesis Research Services, Ground Floor, 239/245 Denison Street Broadmeadow
Newcastle, New South Wales (nsw), Australia · Recruiting
Ramsay Health North Shore, North Shore Private, 03 Westbourne Street
Saint Leonards, New South Wales (nsw), Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
University of the Sunshine Coast Clinical Trials (Birtinya), UniSC Clinical Trials Vitality Village, Level 4, Tenancy 410, 5 Discovery Court
Birtinya, Queensland (qld), Australia · Recruiting
Flinders Medical Centre, Flinders Medical Centre, Flinders
Bedford Park, South Australia (SA), Australia · Recruiting
Box Hill Hospital, Level 1, 5 Arnold street
Box Hill, Victoria, Australia · Recruiting
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
TrialsWest Pty Ltd, 90 Anstruther Road
Mandurah, Western Australia (WA), Australia · Recruiting
TrialsWest Pty Ltd, 226 Main Street
Osborne Park, Western Australia (WA), Australia · Recruiting
Westmead Hospital, Storr Liver Centre, Level 2, A/B Block, Westmead Hospital Corner Hawkesbury and Darcy Roads
Westmead, Westmead, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.